BACKGROUND: During inflammatory cardiomyopathy matrix metalloproteinases are crucially involved in cardiac remodeling. The aim of the present study was to investigate whether the "extracellular matrix metalloproteinase inducer" EMMPRIN (CD147) and its ligand Cyclophilin A (CyPA) are upregulated in inflammatory cardiomyopathy and may serve as diagnostic markers. Therefore, a series of 102 human endomyocardial biopsies were analyzed for the expression of EMMPRIN and CyPA and correlated with histological and immunohistological findings. METHODS AND RESULTS: Endomyocardial biopsies were stained for EMMPRIN and CyPA in addition to standard histology (HE, Trichrom) and immunohistological stainings (MHC-II, CD68, CD3). 39 (38.2%) biopsies met the immunohistological criteria of an inflammatory cardiomyopathy. EMMPRIN, which was predominantly expressed on cardiomyocytes, was slightly (but significantly) upregulated in non inflammatory cardiomyopathies compared to normal histopathological findings and highly upregulated in inflammatory cardiomyopathy compared to both non inflammatory cardiomyopathy and normal histopathology. In contrast, CyPA reveals no enhanced expression in non inflammatory cardiomyopathies and a highly enhanced expression in inflammatory cardiomyopathy, where it is closely associated with leucocytes infiltrates. We found a strong correlation between both EMMPRIN and CyPA with the expression of MHC-II molecules (correlation coefficient 0.475 and 0.527, p<0.05). Moreover, we found a correlation for both EMMPRIN and CyPA with CD68 (correlation coefficient 0.393 and 0.387, p<0.05) and CD3 (correlation coefficient 0.360 and 0.235, p<0.05). CONCLUSION: EMMPRIN is enhanced in both inflammatory and non inflammatory cardiomyopathies and can serve as a marker of myocardial remodeling. CyPA may represent a novel and specific marker for cardiac inflammation.
BACKGROUND: During inflammatory cardiomyopathy matrix metalloproteinases are crucially involved in cardiac remodeling. The aim of the present study was to investigate whether the "extracellular matrix metalloproteinase inducer" EMMPRIN (CD147) and its ligand Cyclophilin A (CyPA) are upregulated in inflammatory cardiomyopathy and may serve as diagnostic markers. Therefore, a series of 102 human endomyocardial biopsies were analyzed for the expression of EMMPRIN and CyPA and correlated with histological and immunohistological findings. METHODS AND RESULTS: Endomyocardial biopsies were stained for EMMPRIN and CyPA in addition to standard histology (HE, Trichrom) and immunohistological stainings (MHC-II, CD68, CD3). 39 (38.2%) biopsies met the immunohistological criteria of an inflammatory cardiomyopathy. EMMPRIN, which was predominantly expressed on cardiomyocytes, was slightly (but significantly) upregulated in non inflammatory cardiomyopathies compared to normal histopathological findings and highly upregulated in inflammatory cardiomyopathy compared to both non inflammatory cardiomyopathy and normal histopathology. In contrast, CyPA reveals no enhanced expression in non inflammatory cardiomyopathies and a highly enhanced expression in inflammatory cardiomyopathy, where it is closely associated with leucocytes infiltrates. We found a strong correlation between both EMMPRIN and CyPA with the expression of MHC-II molecules (correlation coefficient 0.475 and 0.527, p<0.05). Moreover, we found a correlation for both EMMPRIN and CyPA with CD68 (correlation coefficient 0.393 and 0.387, p<0.05) and CD3 (correlation coefficient 0.360 and 0.235, p<0.05). CONCLUSION:EMMPRIN is enhanced in both inflammatory and non inflammatory cardiomyopathies and can serve as a marker of myocardial remodeling. CyPA may represent a novel and specific marker for cardiac inflammation.
Authors: David Heinzmann; Anna Bangert; Anna-Maria Müller; Saskia N I von Ungern-Sternberg; Frederic Emschermann; Tanja Schönberger; Madhumita Chatterjee; Andreas F Mack; Karin Klingel; Reinhard Kandolf; Miroslav Malesevic; Oliver Borst; Meinrad Gawaz; Harald F Langer; Hugo Katus; Gunter Fischer; Andreas E May; Ziya Kaya; Peter Seizer Journal: PLoS One Date: 2015-04-20 Impact factor: 3.240
Authors: Karin A L Mueller; Iris I Mueller; David Eppler; Christine S Zuern; Peter Seizer; Ulrich Kramer; Ina Koetter; Martin Roecken; Reinhard Kandolf; Meinrad Gawaz; Tobias Geisler; Joerg C Henes; Karin Klingel Journal: PLoS One Date: 2015-05-12 Impact factor: 3.240
Authors: Mu-Peng Li; Xiao-Lei Hu; Yong-Long Yang; Yan-Jiao Zhang; Ji-Peng Zhou; Li-Ming Peng; Jie Tang; Xiao-Ping Chen Journal: Int J Environ Res Public Health Date: 2017-02-21 Impact factor: 3.390
Authors: Irene Cuadrado; Maria Jose Garcia Miguel Piedras; Irene Herruzo; Maria Del Carmen Turpin; Borja Castejón; Paula Reventun; Ana Martin; Marta Saura; Jose Luis Zamorano; Carlos Zaragoza Journal: Theranostics Date: 2016-02-15 Impact factor: 11.556
Authors: Karin A L Mueller; Christian Heck; David Heinzmann; Johannes Schwille; Karin Klingel; Reinhard Kandolf; Ulrich Kramer; Michael Gramlich; Tobias Geisler; Meinrad P Gawaz; Juergen Schreieck; Peter Seizer Journal: PLoS One Date: 2016-12-08 Impact factor: 3.240
Authors: Rafael Ramirez-Carracedo; Laura Tesoro; Ignacio Hernandez; Javier Diez-Mata; Marco Filice; Rocío Toro; Manuel Rodriguez-Piñero; Jose Luis Zamorano; Marta Saura; Carlos Zaragoza Journal: Int J Mol Sci Date: 2018-10-19 Impact factor: 5.923